jeudi 3 août 2017

Onco Actu du 3 août 2017

1. Biologie

Scientists deliver knock-out blow to multiple cancers [Cancer Research UK]

2. Etiologie

Gum Disease Tied to Cancer Risk in Older Women [NY Times]

4.12 Biopsies liquides

The ex-Googler who ran a company to detect cancer just stepped down as CEO [CNBC]

GRAIL Appoints Chairman Bill Rastetter to Chief Executive Officer [GRAIL]

4.2 Dép., diag. & prono. - Génome

In-Depth Analysis of Metastatic Cancer Could Enable More Precise Treatments [HHMI]

Gene sequencing of solid tumors sheds light on cancer metastasis [FierceBiotech]

5. Traitements

Targeted radiotherapy limits side effects of breast cancer treatment [Cancer Research UK]

Breast cancer patients could be spared debilitating side effects with targeted treatment, five year study shows [The Telegraph]

5.2 Pharma

Following PhIII breakdown, AstraZeneca cruises toward an FDA decision for its BTK blockbuster hopeful acalabrutinib [EndPoint]

5.3.4 Traitements - AMM (FDA, EMA)

J&J, AbbVie's Imbruvica breaks out of blood-cancer corner with new graft-versus-host approval [FiercePharma]

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy [Janssen]

5.4 Traitements - Economie

Roche invited to submit a CDF proposal for urothelial cancer drug [NICE]

6. Lutte contre les cancers

Last Month in Oncology with Dr. Bishal Gyawali: July 2017 [ecancernews]

GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research [BioMed Central]

6.11 Patients

Survivors of Breast Cancer Differ on Who Should Manage Follow-Up Care [NCI]

6.6 Publications

0.05 or 0.005? P-value Wars Continue [Science-Based Medicine]

6.7 DMP, Big Data & applis

New online navigator helps patients and doctors access experimental treatments [STAT]

Why the ‘gold standard’ of medical research is no longer enough [STAT]

Dr Mark Taylor writes about how NDG principle of ‘no surprises’ in the context of genetic and genomic medicine [National Data Guardian]

6.9 Controverses

US Scientists Edit a Human Embryo—But Superbabies Won’t Come Easy [Wired]

Details Published on CRISPR-treated Embryos (The Scientist]

U.S. scientists edit genome of human embryo, but cast doubt on possibility of ‘designer babies’ [STAT]

The Designer Baby Era Is Not Upon Us [The Atlantic]

Biotechnology: At the heart of gene edits in human embryos [Nature]

CRISPR fixes disease gene in viable human embryos [Nature]

Maine Raises Smoking Age to 21 After Lawmakers Override Veto [NY Times]

In Breakthrough, Scientists Edit a Dangerous Mutation From Genes in Human Embryos [NY Times]

Gene Editing Study in Human Embryos Points toward Clinical Trials [MIT Technology Review]

Deadly gene mutations removed from human embryos in landmark study [The Guardian]